Clinical Trials Browser

Neoplasms

NCT01169532 2021-02-21

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

16 enrolled 7 charts

Lymphoid

Lymphoma

NCT01212627 2021-02-16

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Phase 1 Terminated

12 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00874731 2019-05-06

MK-8669-037

Phase 1 Completed

23 enrolled 14 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01380184 2019-04-19

MK-8669-059

Phase 1 Completed

15 enrolled 15 charts

Neoplasms, Recurrence

NCT01431534 2019-03-01

MK-8669-056

Phase 1 Terminated

20 enrolled 10 charts

Other solid neoplasm

Solid Tumors

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Phase 1 Completed

24 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase 1 Completed

21 enrolled

Other solid neoplasm

Solid Tumors

NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Phase 1 Completed

46 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Phase 1 Completed

33 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1 Completed

65 enrolled

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT00087451 2015-08-19

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Phase 1 Completed

11 enrolled

CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT00288431 2015-07-22

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Phase 1 Completed

37 enrolled

Sarcoma

Neoplasms, Sarcoma

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Phase 1 Completed

16 enrolled

Neoplasm Metastasis, Recurrence

NCT00704054 2015-02-13

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Phase 1 Completed

15 enrolled

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT00781846 2015-02-13

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Phase 1 Completed

17 enrolled

Other solid neoplasm

Solid Tumor

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Phase 1 Completed

147 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01220570 2015-01-21

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1 Completed

63 enrolled

Breast

Breast Neoplasms

NCT01296659 2012-07-12

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Phase 1 Withdrawn

Sarcoma

Clinical Trials

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

MK-8669-037

MK-8669-059

MK-8669-056

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma